Grifols (GRFS) Shares Outstanding (2009 - 2025)
Grifols' (GRFS) quarterly Shares Outstanding (Entity) came in at $680.5 million in Q4 2025, little changed YoY from $679.7 million in Q4 2024, and little changed on a QoQ basis from $679.7 million in Q4 2024.
Grifols (GRFS) Shares Outstanding (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Shares Outstanding (Entity) data on file, last reported at $680.5 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) changed 0.12% year-over-year to $680.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $680.5 million (changed 0.12% YoY) and the FY2025 annual result came in at $680.5 million, changed 0.12% from the prior year.
- Shares Outstanding (Entity) steadied at $680.5 million in Q4 2025, from $679.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $681.6 million in Q4 2021 to a low of $679.7 million in Q4 2024.
- A 5-year average of $680.3 million and a median of $679.8 million in 2022 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2021 — Shares Outstanding (Entity) slipped 0.58% — and 2025, when it grew 0.12%.
- Tracing GRFS's Shares Outstanding (Entity) over 5 years: stood at $681.6 million in 2021, then fell by 0.26% to $679.8 million in 2022, then declined by 0.01% to $679.8 million in 2023, then decreased by 0.01% to $679.7 million in 2024, then gained by 0.12% to $680.5 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $680.5 million (Q4 2025), $679.7 million (Q4 2024), and $679.8 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 680.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 680.51 Mn |
| Dec 31, 2024 | 679.67 Mn |
| Dec 31, 2023 | 679.76 Mn |
| Dec 31, 2022 | 679.81 Mn |
| Dec 31, 2021 | 681.56 Mn |
| Dec 31, 2020 | 685.52 Mn |
| Sep 30, 2020 | 685.12 Mn |
| Mar 31, 2020 | 685.12 Mn |
| Dec 31, 2019 | 685.12 Mn |
| Sep 30, 2019 | 684.71 Mn |
| Mar 31, 2019 | 684.71 Mn |
| Dec 31, 2018 | 684.71 Mn |
| Sep 30, 2018 | 684.20 Mn |
| Jun 30, 2018 | 684.20 Mn |
| Mar 31, 2018 | 684.20 Mn |
| Dec 31, 2017 | 684.20 Mn |
| Jun 30, 2017 | 683.23 Mn |
| Mar 31, 2017 | 683.23 Mn |
| Dec 31, 2016 | 683.23 Mn |
| Sep 30, 2016 | 683.55 Mn |